Avalanche Biotechnologies Inc (ADVM)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Laurent Fischer
Employees:
190
1035 O'BRIEN DRIVE, MENLO PARK, CA 94025
650-272-6269

Adverum Biotechnologies, Inc. develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate. The company was incorporated in 2006 and is headquartered in Redwood City, California.

Data derived from most recent annual or quarterly report
Market Cap 75.595 Million Shares Outstanding99.729 Million Avg 30-day Volume 652.468 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.4
Price to Revenue0.0 Debt to Equity0.0 EBITDA-149.796 Million
Price to Book Value0.4536 Operating Margin0.0 Enterprise Value-108.763 Million
Current Ratio7.451 EPS Growth-0.026 Quick Ratio7.102
1 Yr BETA 0.6055 52-week High/Low 1.82 / 0.53 Profit Margin0.0
Operating Cash Flow Growth-10.7358 Altman Z-Score-3.6696 Free Cash Flow to Firm -102.108 Million
View SEC Filings from ADVM instead.

View recent insider trading info

Avalanche Biotechnologies Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ADVM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ADVM

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-03-17 by RILEY BRIGIT
  • 4: filed on 2023-03-17 by SOPARKAR PETER
  • 4: filed on 2023-03-17 by FISCHER LAURENT
  • 4: filed on 2023-03-03 by RILEY BRIGIT
  • 4: filed on 2023-03-03 by SEYEDKAZEMI SETAREH
  • 4: filed on 2023-03-03 by BECKMAN RICHARD
  • 4: filed on 2023-03-03 by FISCHER LAURENT
  • 3: filed on 2022-12-15 by RUBINSTEIN LINDA M
  • 4: filed on 2022-09-21 by BECKMAN RICHARD
  • 4: filed on 2022-09-21 by SEYEDKAZEMI SETAREH

    • Events (8k)

  • 8-K: filed on 2022-12-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-11-25:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2022-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-06:
    Item 2.05: Cost Associated with Exit or Disposal Activities
  • 8-K: filed on 2022-06-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-06-06:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-29:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-17:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-12-21:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    61.9 Thousand total shares from 3 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    FISCHER LAURENT CEO, PRESIDENT AND DIRECTOR

    • Officer
    • Director
    		 692,141 2023-03-15 5

    SOPARKAR PETER CHIEF OPERATING OFFICER

    • Officer
    		 265,891 2023-03-15 5

    RILEY BRIGIT CHIEF SCIENTIFIC OFFICER

    • Officer
    		 117,435 2023-03-15 4

    SEYEDKAZEMI SETAREH CHIEF DEVELOPMENT OFFICER

    • Officer
    		 0 2023-03-01 4

    BECKMAN RICHARD CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-03-01 5

    RUBINSTEIN LINDA M CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2022-12-12 1

    RAKOW JOHN SVP, GENL COUNSEL, ACTING CFO

    • Officer
    		 118,070 2022-09-14 3

    WHITCUP SCOTT M

    • Director
    		 40,000 2022-06-10 1

    MACHADO PATRICK

    • Director
    		 52,500 2022-06-10 1

    SCOPA JAMES PAUL

    • Director
    		 40,000 2022-06-10 1

    TUCKSON REED VAUGHN

    • Director
    		 40,000 2022-06-10 1

    SVORONOS DAWN

    • Director
    		 40,000 2022-06-10 2

    LUPHER, JR. MARK L.

    • Director
    		 40,000 2022-06-10 1

    PECOTA NANCY E PRINCIPAL ACCOUNTING OFFICER

    • Officer
    		 0 2022-06-06 1

    D'SOUZA RUPERT CHIEF FINANCIAL OFFICER

    • Officer
    		 20,850 2022-05-13 1

    OZDEN RABIA GURSES

    • Director
    		 0 2022-03-17 0

    HONG SOO

    • Director
    		 80,000 2022-03-17 0

    CLARK JULIE CHIEF MEDICAL OFFICER

    • Officer
    		 164,723 2021-09-30 0

    THRIFT JACK ANTHONY INTERIM CFO

    • Officer
    		 0 2021-09-02 0

    THEDINGA ANGELA CHIEF TECHNOLOGY OFFICER

    • Officer
    		 270,000 2021-08-06 0

    DERESPINO CHRISTOPHER SEE REMARKS

    • Officer
    		 0 2021-06-24 0

    GASMI MEHDI

    • Director
    		 40,000 2021-05-12 0

    WOIWODE THOMAS

    • Director
    		 40,000 2021-05-12 0

    PATTERSON LEONE D PRESIDENT AND CFO

    • Officer
    		 0 2021-02-16 0

    OSBORNE AARON CHIEF MEDICAL OFFICER

    • Officer
    		 0 2021-02-16 0

    CARTER ERIC G

    • Director
    		 0 2020-06-23 0

    HEMRAJANI REKHA

    • Director
    		 0 2020-06-23 0

    LEUNG THOMAS CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2020-02-20 0

    FINER MITCHELL H.

    • FORMER DIRECTOR
    		 No longer subject to file 2019-07-31 0

    SPIVEY RICHARD N.

    • Director
    		 0 2019-07-31 0

    CHENG JENNIFER C. GENERAL COUNSEL

    • Officer
    		 0 2019-02-14 0

    CLEVELAND PAUL B

    • Director
    		 0 2018-05-31 0

    COUNTOURIOTIS ATHENA SVP, CHIEF MEDICAL OFFICER

    • Officer
    		 0 2018-02-15 0

    SALZMAN AMBER PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2018-02-15 0

    SCHWARTZ STEVEN DANIEL

    • Director
    		 398,991 2017-06-12 0

    BARONE SAMUEL B. SVP, CLINICAL DEVELOPMENT

    • Officer
    		 172,335 2017-02-09 0

    VERSANT VENTURES IV, LLC

    VERSANT VENTURE CAPITAL IV, L.P.

    VERSANT IV LUXCO S.A R.L.

    VERSANT CAPITAL IV (SWITZERLAND) GMBH

    • 10% Owner
    		 7,003,892 2016-05-11 0

    RUSSO CARLO EVP AND CHIEF MEDICAL OFFICER

    • Officer
    		 0 2016-05-11 0

    WACHTER PAUL

    • Director
    		 69,112 2016-02-29 0

    MCLAUGHLIN JOHN PETER

    • Director
    		 36,893 2016-02-12 0

    BLUMENKRANZ MARK S.

    • Director
    		 562,915 2016-02-12 0

    RUBIO ROMAN G. SVP, TRANSLATIONAL MEDICINE

    • Officer
    		 165,650 2016-02-12 0

    BRAUN SHIRLEY VP, HUMAN RESOURCES

    • Officer
    		 161,140 2016-02-12 0

    SWARTZBURG MICHAEL PRINCIPAL ACCOUNTING OFFICER

    • Officer
    		 82,113 2016-02-12 0

    BAIN LINDA CHIEF FINANCIAL OFFICER

    • Officer
    		 41,930 2015-08-21 0

    HULL HANS CHIEF EXECUTIVE OFFICER

    • Officer
    		 137,210 2015-08-21 0

    CHALBERG THOMAS W. CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 1,099,401 2015-06-10 0

    GUERIN JOHN PATRICK ET AL

    • Director
    • 10% Owner
    		 200,000 2015-05-27 0

    ZYGTECH, LLC

    • 10% Owner
    		 No longer subject to file 2015-04-13 0

    REGENERON PHARMACEUTICALS INC

    • 10% Owner
    		 No longer subject to file 2014-08-05 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P.

    DEERFIELD MGMT III, L.P.

    DEERFIELD MANAGEMENT CO

    DEERFIELD PRIVATE DESIGN FUND III, L.P.

    DEERFIELD PARTNERS, LP

    DEERFIELD INTERNATIONAL MASTER FUND, L.P.

    • 10% Owner
    • POSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUP
    		 No longer subject to file 2014-08-05 0

    VENROCK ASSOCIATES VI, L.P.

    VENROCK PARTNERS VI, L.P.

    VENROCK MANAGEMENT VI, LLC

    VENROCK PARTNERS MANAGEMENT VI, LLC

    VENROCK HEALTHCARE CAPITAL PARTNERS LP

    VHCP CO-INVESTMENT HOLDINGS, LLC

    VHCP MANAGEMENT, LLC

    HOVE ANDERS D

    KOH BONG Y

    • 10% Owner
    		 4,330,942 2014-08-05 0

    VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P.

    VHCP CO-INVESTMENT HOLDINGS II, LLC

    VHCP MANAGEMENT II, LLC

    • 10% Owner
    		 4,330,942 2014-08-05 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P.

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    DEERFIELD MGMT III, L.P.

    DEERFIELD PRIVATE DESIGN FUND III, L.P.

    • 10% Owner
    • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
    		 0 2014-07-30 0

    VENROCK ASSOCIATES VI, L.P.

    VENROCK PARTNERS VI, L.P.

    VENROCK MANAGEMENT VI, LLC

    VENROCK PARTNERS MANAGEMENT VI, LLC

    VENROCK HEALTHCARE CAPITAL PARTNERS LP

    VHCP CO-INVESTMENT HOLDINGS, LLC

    VHCP MANAGEMENT, LLC

    ROBERTS BRYAN E

    HOVE ANDERS D

    • 10% Owner
    		 0 2014-07-30 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    FISCHER LAURENT - Director - Officer CEO, PRESIDENT AND DIRECTOR

    		2023-03-17 18:01:25 -0400 2023-03-15 S 41,239 $0.78 d 692,141 direct -0.5089 0.0 1 -0.5089 2

    RILEY BRIGIT - Officer CHIEF SCIENTIFIC OFFICER

    		2023-03-17 18:02:59 -0400 2023-03-15 S 7,299 $0.78 d 117,435 direct -0.5089 0.0 1 -0.5089 2

    SOPARKAR PETER - Officer CHIEF OPERATING OFFICER

    		2023-03-17 18:02:15 -0400 2023-03-15 S 13,360 $0.78 d 265,891 direct -0.5089 0.0 1 -0.5089 2

    SEYEDKAZEMI SETAREH - Officer CHIEF DEVELOPMENT OFFICER

    		2023-03-03 17:24:02 -0500 2023-03-01 A 250,000 a 250,000 direct

    BECKMAN RICHARD - Officer CHIEF MEDICAL OFFICER

    		2023-03-03 17:23:14 -0500 2023-03-01 A 225,000 a 225,000 direct

    RILEY BRIGIT - Officer CHIEF SCIENTIFIC OFFICER

    		2023-03-03 17:24:23 -0500 2023-03-01 A 250,000 a 250,000 direct

    FISCHER LAURENT - Director - Officer CEO, PRESIDENT AND DIRECTOR

    		2023-03-03 17:21:33 -0500 2023-03-01 A 930,000 a 930,000 direct

    SOPARKAR PETER - Officer CHIEF OPERATING OFFICER

    		2023-03-03 17:22:20 -0500 2023-03-01 A 400,000 a 400,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 22:15:03 UTC 3.0059 1.8141 500000
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 21:45:03 UTC 2.9655 1.8545 500000
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 21:15:03 UTC 2.9655 1.8545 500000
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 20:45:03 UTC 2.9657 1.8543 500000
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 20:15:04 UTC 2.9657 1.8543 500000
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 19:45:03 UTC 2.9657 1.8543 500000
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 19:15:04 UTC 2.9657 1.8543 500000
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 18:45:04 UTC 2.9736 1.8464 500000
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 18:15:03 UTC 2.9736 1.8464 500000
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 17:45:03 UTC 2.9736 1.8464 500000
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 17:15:03 UTC 2.9736 1.8464 500000
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 16:45:03 UTC 2.975 1.845 500000
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 16:15:03 UTC 2.975 1.845 500000
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 15:45:03 UTC 2.975 1.845 500000
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 15:15:03 UTC 2.975 1.845 500000
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 14:45:03 UTC 2.975 1.845 500000
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 14:15:03 UTC 2.975 1.845 700000
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 13:45:03 UTC 2.7458 1.8242 700000
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 13:15:04 UTC 2.7458 1.8242 700000
    ADVERUM BIOTECHNOLOGIES INC ADVM 2023-03-24 12:45:03 UTC 2.7458 1.8242 700000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Trust for Professional Managers- Convergence Market Neutral Fund ADVM -5066.0 shares, $-61805.2 2020-08-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments